Previous Pause Next
Home >> News Center >> Features >> The Burrill Features >>
Fixing Drug Development with the Wisdom of Crowds PDF Print E-mail
User Rating :  / 0
Sunday, 05 February 2012 17:13

Transparency Life Sciences is betting on the wisdom of crowds when it comes to designing clinical trials. The company believes that it can address problems of falling R&D productivity that have plagued the pharmaceutical industry by using crowdsourcing and digital health technologies to design and conduct clinical trials more efficiently. We spoke to Tomasz Sablinski, CEO of Transparency, about what’s broken in drug development today, what his company is doing to change traditional approaches, and what need to do to prove its model actually works.

The Burrill Report (February 6, 2012): Fixing Drug Development with the Wisdom of Crowds (.MP3,14.48 Mb) 

 
FairExcellent 

Add comment  |   Add to my library  |  Forward this article

login to leave comment